Document is current

Article History

Received: 6 December 2025

Revised: 19 December 2025

Accepted: 2 February 2026

First Online: 17 February 2026

Competing interests

: CR declares an advisory role for Janssen and Takeda and received honoraria from Janssen. MT, MM, SH and HM are current employees of MLL Munich Leukemia Laboratory. LL declares an advisory role for GSK, Sanofi, Janssen, and Pfizer. She received honoraria from Adaptive, Amgen, AbbVie, Janssen, BMS/Celgene, Pfizer, Sanofi, GSK, Takeda, AstraZeneca and research funding from AbbVie and GSK (both to the institution); travel/conference attendance support from Sanofi, Oncopeptides, J&J and Amgen. JM declares an advisory role for J&J and Pfizer and received honoraria from J&J, Sanofi, Pfizer and Skyline Dx. CH and TH are owners of MLL Munich Leukemia Laboratory. AB declares advisory roles for BMS, GSK, Janssen, Sanofi, Menarini-StemLine, AstraZeneca and Pfizer. She has received honoraria from BMS, GSK, Janssen, Sanofi, Menarini-StemLine, AstraZeneca and Pfizer and travel support from Janssen, BMS and AstraZeneca. KCW declares an advisory role for AbbVie, Adaptive, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Cellcentric, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline and Takeda. She received honoraria from AbbVie, Adaptive, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche Pharma, Sanofi, Stemline and Takeda and research funding from Amgen, Bristol Myers Squibb/Celgene, Janssen, Sanofi, GSK, AbbVie (each to the institution). EPN declares a consulting role/honoraria from Bristol-Myers Squibb, Janssen, Sanofi, and Pfizer. HE declares a consulting or advisory role for BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis and Roche. He received research funding from BMS/Celgene, Janssen, Amgen, GSK, Sanofi and Novartis, honoraria from BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis and Roche and travel support from BMS/Celgene, Janssen, Amgen and Sanofi. KMK declares research funding and honoraria from Janssen and is supported by the DFG and the Stifterverband. JMW declares an advisory role for Janssen, BMS, GSK, AbbVie and Pfizer, as well as research funding from BMS. LR declares a consulting or advisory role for BMS, Amgen, GSK, Janssen, Sanofi, and Pfizer. He has received research funding from BMS and honoraria from BMS, Janssen, Pfizer, GSK, and Sanofi. The other authors declare no competing interests.